Cortexyme shares tumbled more than 70% in premarket trading.Cortexyme Inc said on Tuesday its experimental oral pill failed to meet the main goals of improving cognitive and functional abilities in patients with mild-to-moderate Alzheimer's disease in a study.
精彩评论